Innate Pharma : Update S1 2022 : accord AZN et lacutamab en points saillants
>158 M€ de cash à fin juin 2022 - Innate Pharma publie ce matin ses chiffres financiers pour le premier semestre 2022. Le résultat opérationnel sur la période ressort en territoire positif à 8.5 M€ (vs -19.2 M€ en 2021) sous l’effet de l’augmentation des revenus opérationnels (45.6 M€ vs 14.6 M€ une année auparavant) provenant principalement des paiements reçus dans le cadre des accords de collaboration conclus avec AstraZeneca et Sanofi.La position de trésorerie...Innate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.